Niraparib, Dostarlimab, and Bevacizumab as Combination Therapy in Pretreated, Advanced Platinum-Resistant Ovarian Cancer: Findings From Cohort A of the OPAL Phase II Trial
Liu J, Gaillard S, Hendrickson A, Yeku O, Diver E, Jackson C, Arend R, Ratner E, Samnotra V, Gupta D, Chung J, Zhang H, Compton N, Baines A, Bacqué E, Liu X, Felicetti B, Konecny G. Niraparib, Dostarlimab, and Bevacizumab as Combination Therapy in Pretreated, Advanced Platinum-Resistant Ovarian Cancer: Findings From Cohort A of the OPAL Phase II Trial. JCO Precision Oncology 2024, 8: e2300693. PMID: 38754056, PMCID: PMC11371093, DOI: 10.1200/po.23.00693.Peer-Reviewed Original ResearchConceptsPlatinum-resistant ovarian cancerObjective response ratePD-L1 statusAdverse eventsHR deficiencyPD-L1Ovarian cancerCohort AInvestigator-assessed objective response rateTreatment-emergent adverse eventsOn-treatment samplesTreated with niraparibDisease control rateParticipants discontinued treatmentPhase II trialTumor molecular profilingPoor treatment responseBiomarker end pointsPostbaseline scanTriplet therapyRECIST v1.1II trialPrognostic factorsCombination therapyImmune activation
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply